Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV0328 in Healthy Volunteers
NCT02853617Phase 2Completed
- Sponsor
- Alopexx, Inc.
- Start
- Mar 2017
- Primary completion
- Apr 2018
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of PNAG vaccine in pneumococcal infection, meningococcal infection, staphylococcal infection, sponsored by Alopexx, Inc.. Started Mar 2017; status: completed.
02
Drugs
PNAG vaccine
03
Conditions
pneumococcal infectionmeningococcal infectionstaphylococcal infection
Beyond the preview
Go deeper on NCT02853617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02853617.